We are live on ! Find out more
BLRX

BioLineRX
BLRX

14 hedge funds and large institutions have $104K invested in BioLineRX in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.9% less ownership

Funds ownership: 1.55% → 0.65% (-0.9%)

18% less funds holding

Funds holding: 17 → 14 (-3)

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

65% less capital invested

Capital invested by funds: $302K → $104K (-$198K)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

97% less call options, than puts

Call options by funds: $2K | Put options by funds: $77K

Holders
14
Holders Change
-3
Holders Change %
-17.65%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
3
Closed
6
Calls
$2K
Puts
$77K
Net Calls
-$75K
Net Calls Change
-$613K

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$25.6K
2
Morgan Stanley
Morgan Stanley
New York
+$17.7K
3
TRCT
Tower Research Capital (TRC)
New York
+$156
4
Rockefeller Capital Management
Rockefeller Capital Management
New York
+$48

Top Sellers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
-$63.1K
2
Simplex Trading
Simplex Trading
Illinois
-$56.2K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$44.5K
4
Citadel Advisors
Citadel Advisors
Florida
-$19.8K
5
Citigroup
Citigroup
New York
-$18.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$37.9K -$19.8K -4,934 -33%
UBS Group
2
UBS Group
Switzerland
$24.1K +$25.6K +6,387 New
Morgan Stanley
3
Morgan Stanley
New York
$22.5K +$17.7K +4,410 +286%
RhumbLine Advisers
4
RhumbLine Advisers
Massachusetts
$11.6K -$4.83K -1,205 -28%
Wells Fargo
5
Wells Fargo
California
$6.62K – – –
NRG
6
Nemes Rush Group
Michigan
$945 – – –
NA
7
NewEdge Advisors
Louisiana
$405 – – –
TRCT
8
Tower Research Capital (TRC)
New York
$147 +$156 +39 New
Rockefeller Capital Management
9
Rockefeller Capital Management
New York
$45 +$48 +12 New
Bank of America
10
Bank of America
North Carolina
$8 – – –
DB
11
Danske Bank
Denmark
$8 – – –
SS
12
SBI Securities
Japan
$8 – – –
Osaic Holdings
13
Osaic Holdings
Arizona
$3 – – –
Simplex Trading
14
Simplex Trading
Illinois
– -$56.2K -14,009 -99%
TSS
15
Two Sigma Securities
New York
– -$63.1K -13,816 Closed
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
– -$44.5K -11,098 Closed
Citigroup
17
Citigroup
New York
– -$18.3K -4,005 Closed
National Bank of Canada
18
National Bank of Canada
Quebec, Canada
– -$914 -200 Closed
Raymond James Financial
19
Raymond James Financial
Florida
– -$329 -72 Closed
Fifth Third Bancorp
20
Fifth Third Bancorp
Ohio
– -$114 -25 Closed

BLRX Hedge Fund Activity: Q3 2025 in Review

14 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q3 2025, worth a combined $104K — down 65% from $302K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of BLRX and 3 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, opening a new position worth an estimated $25.6K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $63.1K sold.

  • 14 institutional investors held BioLineRX (BLRX) as of Q3 2025, down from 17 in Q2 2025.
  • Funds reported $104K of BioLineRX stock for Q3 2025, down 65% quarter-over-quarter.
  • 3 funds opened new BioLineRX positions in Q3 2025 and 6 closed out, a net change of -3 holders.
  • The largest BioLineRX buyer in Q3 2025 was UBS Group, an estimated $25.6K added.
  • The largest BioLineRX seller in Q3 2025 was Two Sigma Securities, an estimated $63.1K sold.

Based on aggregated 13F filings for Q3 2025.